PROK
ProKidney Corp.NASDAQHealthcare$1.90+8.57%ClosedMarket Cap: $550.1M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.25
P/S
615.99
EV/EBITDA
-3.00
DCF Value
$0.88
FCF Yield
-24.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
-218.8%
Operating Margin
-18477.8%
Net Margin
-7725.2%
ROE
6.9%
ROA
-20.6%
ROIC
-54.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $225.0K | -544.0% | $-45.4M | $-19.2M | $-0.14 | — |
| FY 2025 | $893.0K | -540.8% | $-165.0M | $-69.0M | $-0.52 | — |
| Q3 2025 | $217.0K | -544.2% | $-38.5M | $-16.5M | $-0.12 | — |
| Q2 2025 | $221.0K | 100.0% | $-39.7M | $-16.6M | $-0.13 | — |
| Q1 2025 | $230.0K | 100.0% | $-41.4M | $-16.7M | $-0.13 | — |
| Q4 2024 | $76.0K | 100.0% | $-51.6M | $-21.3M | $-0.17 | — |
| FY 2024 | $76.0K | 100.0% | $-183.7M | $-61.2M | $-0.62 | — |
| Q3 2024 | $0.00 | NaN% | $-49.0M | $-17.9M | $-0.14 | — |
| Q2 2024 | $0.00 | NaN% | $-43.1M | $-12.5M | $-0.16 | — |
| Q1 2024 | $0.00 | NaN% | $-40.1M | $-9.5M | $-0.16 | — |
| Q4 2023 | $0.00 | NaN% | $-24.2M | $-5.7M | $-0.10 | — |
| FY 2023 | $0.00 | NaN% | $-151.5M | $-35.5M | $-0.57 | — |